Spotlight Stories

  1. Verve Therapeutics: How To Build A Gene Editing Biotech 1/3/2023

    Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.

  2. Peter Marks: Prioritizing Better Communication And Faster Product Reviews 1/3/2023

    In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.

  3. Executive Outlook: Crafting New Solutions For Persisting Problems 12/1/2022

    Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).

  4. Will The Finance And Funding Pendulum Swing Back To Black In 2023? 12/1/2022

    Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

  5. Biopharma Public Opinion, Pricing, Politics 12/1/2022

    Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.

  6. Building New Solutions For 2023 In Manufacturing And Supply Chain 12/1/2022

    In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.

  7. Pioneering In-House, Continuous Manufacturing 11/1/2022

    Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.

  8. Fueling A Focused Drug Development Model 11/1/2022

    Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end, and commercialization on the other.

  9. Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising 11/1/2022

    The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.

  10. Managing Through Mixed Trial Results And An Economic Downturn 11/1/2022

    From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory approval, Cary Claiborne has been faced with multiple challenges since becoming CEO of Adial Pharma in August.